Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase 3 3Phase 1/2 3

Status

Withdrawn 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Skin Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × linrodostat × Clear all
NCT03329846 2021-07-09

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Bristol-Myers Squibb

Phase 3 Completed
20 enrolled 10 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT03386838 2019-04-18

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Bristol-Myers Squibb

Phase 3 Withdrawn
Head & Neck

Head and Neck Neoplasms

NCT03417037 2018-04-30

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Bristol-Myers Squibb

Phase 3 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡